Health&Life Co

Health&Life Co Net Debt

The Net Debt of Health&Life Co (1781.TWO) as of Oct 27, 2026 is 190.02 M TWD. In the previous year, Net Debt was 190.80 M TWD — a change of -0.41% (lower).

Net Debt

190.02 MTWD

YoY

-0.41%

Last updated:

Net Debt of Health&Life Co is 2025 190.02 M TWD. Net Debt of Health&Life Co was 2024 190.80 M TWD. It decreases by -0.41% lower compared to the previous year.

The Health&Life Co Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2018
-67.78 M TWD
Jan 1, 2019
-13.21 M TWD
Jan 1, 2020
-219.91 M TWD
Jan 1, 2021
44.14 M TWD
Jan 1, 2022
31.53 M TWD
Jan 1, 2023
19.22 M TWD
Jan 1, 2024
190.80 M TWD
Jan 1, 2025
190.02 M TWD
The Health&Life Co Net Debt history
YEARNet DebtYoY
190.02 MTWD-0.41%
190.80 MTWD+892.69%
19.22 MTWD-39.04%
31.53 MTWD-28.57%
44.14 MTWD-120.07%
-219.91 MTWD+1,564.23%
-13.21 MTWD-80.50%
-67.78 MTWD-56.78%
-156.83 MTWD+2.39%
-153.16 MTWD-34.56%
-234.06 MTWD+8.35%
-216.03 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Health&Life Co Stock analysis

What does Health&Life Co do? Health&Life Co Ltd generates revenue through the manufacturing and distribution of cardiovascular disease, in-vitro diagnostics, and respiratory care products. The company's primary products include electronic sphygmomanometers such as blood pressure monitors, nebulizers, and blood glucose monitoring systems, which measure and record systolic and diastolic blood pressure and glucose levels. These products are sold domestically in Taiwan and internationally to overseas markets. The firm targets healthcare providers, clinics, and consumers seeking home health monitoring solutions for chronic conditions like hypertension and diabetes. The company's product portfolio focuses on electronic sphygmomanometers, which are essential for daily health monitoring. By offering devices that measure blood pressure and glucose levels, Health&Life Co Ltd caters to patients managing cardiovascular and metabolic diseases. The domestic market in Taiwan serves as a key sales channel, while overseas markets provide additional growth opportunities for the firm's diagnostic and respiratory care products. Health&Life Co Ltd's business model relies on direct sales of medical devices to healthcare institutions and end-users. The firm's electronic sphygmomanometers, including blood pressure monitors and blood glucose systems, are distributed through both domestic and international channels. This approach ensures consistent revenue streams from the ongoing demand for home health monitoring equipment among patients with chronic conditions. Health&Life Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Health&Life Co stock

Net Debt of Health&Life Co is 190.02 M TWD in 2025.

Net Debt of Health&Life Co changed from 190.80 M TWD to 190.02 M TWD, representing a -0.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Health&Life Co since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Health&Life Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Health&Life Co

All Key Metrics — Health&Life Co